Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients.
Combined treatment of psoriasis with methotrexate and etretinate may be associated with hepatoxicity. This study investigated the potential effects of steady state etretinate administration on methotrexate pharmacokinetics in six psoriatic patients. When compared with a matched group a significantly higher mean value for the maximum plasma concentration Cmax (992 nmol/L +/- 94 SE vs 721 nmol/L +/- 35 SE) for methotrexate was found (P less than .05) after intramuscular administration of 0.2 mg/kg body weight of the drug. In accordance with this finding mean values of the time (tmax) to reach Cmax, half-life of the absorption (t1/2ka) and the apparent volume of distribution at steady state Vss were also lower than in the control groups but did not deviate significantly. Total clearance differed very little and insignificantly between the two groups. Absorption and disposition rates of etretinate during combined treatment with methotrexate were not significantly altered compared with previous results in psoriatic patients only receiving etretinate. Overall, these results indicate that the apparently increased risk for developing hepatotoxic reactions during coadministration of methotrexate and etretinate cannot be explained by drug accumulation due to pharmacokinetic interaction. A possible influence on potential hepatotoxicity of an increase of Cmax for methotrexate cannot be excluded.
Larsen
F G
FG
Department of Dermatology, Marselisborg Hospital, Aarhus, Denmark.
Nielsen-Kudsk
F
F
Jakobsen
P
P
Schrøder
H
H
Kragballe
K
K
D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005050:Etretinate / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D008727:Methotrexate / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy / Q000378:metabolism*
D005050:Etretinate; D008727:Methotrexate